Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Next Generation Sequencing Asia 2016: Clinical Applications

Chien-Hsiang Tang's Biography



Chien-Hsiang Tang, R&D Director, LihPao Life Science Corp.

Dr. Tang Chien-Hsiang is the CEO of Lihpao Biotechnology in Xiamen and R&D director in Lihpao LifeScience . His previous works involved in different aspects of life science including drug development, medical devices and oncology. Currently Dr. Tang and Lihpao LifeScience is collaborating closely with Taipei Veterans General Hospital along with many hospitals in Taiwan and China, his vision is to bring affordable precision diagnostic tools to the patients in need. and he believes the tools like NGS will be a very powerful tool to help general practitioners for the coming future.

Chien-Hsiang Tang Image

The New Era of Cancer Precision Treatment: NGS-based Clinical Companion Diagnostics

Friday, 2 December 2016 at 12:00

Add to Calendar ▼2016-12-02 12:00:002016-12-02 13:00:00Europe/LondonThe New Era of Cancer Precision Treatment: NGS-based Clinical Companion DiagnosticsNext Generation Sequencing Asia 2016: Clinical Applications in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com

Precision Medicine has been an emerging approach for cancer diagnostic treatments through improvement on technology and reduction on supplies. Countless advances in Precision Medicine have already led to powerful new discoveries and treatments. Over the years, our laboratory dedicates to the research on personal genetic profiling with NGS (next generational sequencing) platform. With strong clinical practices in Taipei Veteran General Hospital, the laboratory forwards the molecular diagnostic practice to the cancer patients. Under College of American Pathologists (CAP) accredited laboratory, our current services include Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), and Comprehensive target-drug-panels, and more beneficial servicing panels will be launched soon. Through target-drug related NGS genetic profiling, the effectiveness of medication could be greatly improved, thus, reduced the possibility of cancer reoccurrence for patients.


Add to Calendar ▼2016-12-01 00:00:002016-12-02 00:00:00Europe/LondonNext Generation Sequencing Asia 2016: Clinical ApplicationsNext Generation Sequencing Asia 2016: Clinical Applications in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com